MARATTO

article · The Journal of Infection in Developing Countries

OXA-48-producing Enterobacteriaceae in North of Morocco: Data from regional hospital of Tangier

Abstract

INTRODUCTION: This is a three-year retro-prospective study aimed at assessing the prevalence of carbapenem-resistant Enterobacteriaceae and to study three-year retrospective study aimed at determining the prevalence of carbapenem-resistant Enterobacteriaceae and analyzing the characteristics of OXA-48 producers. METHODOLOGY: Six thousand one hundred eighteen bacteriological samples were assessed at Mohamed V Regional Hospital microbiology laboratory in Tangier, Morocco. RESULTS: Of the 1,228 identified Enterobacteriaceae, Escherichia coli was the most isolated bacteria (68%). Fifty-eight Enterobacteriaceae were resistant to carbapenem (4.7%). Klebsiella pneumoniae, Escherichia coli, and Enterobacter cloacae were the most common carbapenemase-producing isolates (43.1%, 27.5%, and 20.7%, respectively). All isolates were resistant to ertapenem, 62% to imipenem, whereas the lowest rate of resistance to carbapenems was against meropenem (51%). Among carbapenemase-producing isolates, 13.8% also produced extended-spectrum beta-lactamase. Most carbapenemase-producing Enterobacteriaceae isolates harbored the gene blaOXA-48 (84.5%). CONCLUSIONS: Our findings highlight the alarming situation of the probable misuse of antibiotics. Awareness-raising sessions about the appropriate use of antibiotics and improving hospital hygiene are highly needed.

Research topics

  • Antibiotic Resistance in Bacteria
  • Infections and bacterial resistance
  • Enterobacteriaceae and Cronobacter Research

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.3855/jidc.18564

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.